The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas
Open accessAbstract
Activating point mutations of the BRAF gene have been recently reported in papillary thyroid carcinomas. In this study, we analyzed 320 thyroid tumors and six anaplastic carcinoma cell lines and detected BRAF mutations in 45 (38%) papillary carcinomas, two (13%) poorly-differentiated carcinomas, three (10%) anaplastic carcinomas, and five (83%) thyroid anaplastic carcinoma cell lines but not in follicular, Hürthle cell, and medullary carcinomas, follicular and Hürthle cell adenomas, or benign hyperplastic nodules. All mutations involved a T→A transversion at nucleotide 1796. In papillary carcinomas, BRAF mutations were associated with older age, classic papillary carcinoma or tall cell variant histology, extrathyroidal extension, and more frequent presentation at stages III and IV. All BRAF-positive poorly differentiated and anaplastic carcinomas contained areas of preexisting papillary carcinoma, and mutation was present in both the well-differentiated and dedifferentiated components. These data indicate that BRAF mutations are restricted to papillary carcinomas and poorly differentiated and anaplastic carcinomas arising from papillary carcinomas. They are associated with distinct phenotypical and biological properties of papillary carcinomas and may participate in progression to poorly differentiated and anaplastic carcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 6×
“00/0 The Journal of Clinical Endocrinology & Metabolism 88(11):5399–5404 Printed in U.”
BackgroundInfluentialFirminger, H. I. (1968) · Armed Forces Institute of Pathology eBooks · Cited by 3,044
AJCC Cancer Staging Manual. 6th ed
Greene, F., Page, D., Id, F., Fritz, J., Balch, C., & Haller, D. (2002) · Cited by 2,324
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,510
Self-citationRAF/RAS oncogenes and mismatch-repair status
Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Nature · doi:10.1038/418934a · Cited by 1,224 · cited 1×
“Nucleotide 1796, the only mutational site in thyroid carcinomas, was the most frequently affected hot spot in other types of human cancers where BRAF is mutated, such as malignant melanoma and colorectal carcinoma (11, 12).”
BackgroundBRAF Mutation in Papillary Thyroid Carcinoma
Cohen, Y., Xing, M., Mambo, E., Guo, Z., Wu, G., Trink, B., Beller, U., Westra, W. H., Ladenson, P. W., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.8.625 · Cited by 922
PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma
Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C.-J., Mueller, E., Spiegelman, B. M., & Fletcher, J. A. (2000) · Science · doi:10.1126/science.289.5483.1357 · Cited by 784
Rosaí, J., Carcangiu, M. L., & DeLellis, R. A. (1992) · Armed Forces Institute of Pathology eBooks · Cited by 492
Anaplastic carcinoma of the thyroid: A clinicopathologic study of 121 cases
Venkatesh, Y. S. S., Ordonez, N. G., Schultz, P. N., Hickey, R. C., Goepfert, H., & Samaan, N. A. (1990) · Cancer · doi:10.1002/1097-0142(19900715)66:2<321::aid-cncr2820660221>3.0.co;2-a · Cited by 486
High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.
Lemoine, N. R., Mayall, E. S., Wyllie, F. S., Williams, E. D., Goyns, M. H., Stringer, B. M. J., & Wynford‐Thomas, D. (1989) · PubMed · Cited by 417
A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases
Fusco, A., Grieco, M., Santoro, M., Berlingieri, M. T., Pilotti, S., Pierotti, M. A., Porta, G. D., & Vecchio, G. (1987) · Nature · doi:10.1038/328170a0 · Cited by 413
Self-citationRet oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.
Santoro, M., Carlomagno, F., Hay, I. D., Herrmann, M. A., Grieco, M., Melillo, R., Pierotti, M. A., Bongarzone, I., Della Porta, G., & Berger, N. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115743 · Cited by 390
Self-citationZhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H., & Nikiforov, Y. E. (2003) · American Journal of Clinical Pathology · doi:10.1309/nd8d-9laj-trct-g6qd · Cited by 371
Self-citationAldinger, K. A., Samaan, N. A., Ibanez, M., & Hill, C. S. (1978) · Cancer · doi:10.1002/1097-0142(197806)41:6<2267::aid-cncr2820410627>3.0.co;2-7 · Cited by 364
Point Mutations of Ras Oncogenes are an Early Event in Thyroid Tumorigenesis
Namba, H., Rubin, S. A., & Fagin, J. A. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-10-1474 · Cited by 356
Self-citationZhu, Z., Gandhi, M., Nikiforova, M. N., Fischer, A. H., & Nikiforov, Y. E. (2003) · American Journal of Clinical Pathology · doi:10.1309/nd8d9lajtrctg6qd · Cited by 355
Self-citation(1992) · American Journal of Otolaryngology · doi:10.1016/0196-0709(92)90038-u · Cited by 350
PAX8-PPARγ Rearrangement in Thyroid Tumors: RT-PCR and Immunohistochemical Analyses
Nikiforova, M. N., Biddinger, P. W., Caudill, C. M., Kroll, T. G., & Nikiforov, Y. E. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200208000-00006 · Cited by 349
Self-citationPrognostic Implications of the Tall Cell Variant of Papillary Thyroid Carcinoma
Johnson, T. L., Lloyd, R. V., Thompson, N. W., Beierwaltes, W. H., & Sisson, J. C. (1988) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198801000-00003 · Cited by 294
Greco, A., Pierotti, M. A., Bongarzone, I., Pagliardini, S., Lanzi, C., & Porta, G. (1992) · PubMed · Cited by 226
Nikiforov, Y. E., Nikiforova, M. N., Gnepp, D. R., & Fagin, J. A. (1996) · PubMed · Cited by 127
Self-citationPANG, X.-P., HERSHMAN, J. M., CHUNG, M., & PEKARY, A. E. (1989) · Endocrinology · doi:10.1210/endo-125-4-1783 · Cited by 116
Tall Cell Variant: An Aggressive Form of Papillary Thyroid Carcinoma
Prendiville, S., Burman, K. D., Ringel, M. D., Shmookler, B. M., Deeb, Z. E., Wolfe, K., Azumi, N., Wartofsky, L., & Sessions, R. B. (2000) · Otolaryngology · doi:10.1016/s0194-5998(00)70047-7 · Cited by 106
Anaplastic Thyroid Cancer Evolved From Papillary Carcinoma
Wiseman, S. M., Loree, T. R., Hicks, W. L., Rigual, N., Winston, J. S., Tan, D., Anderson, G. R., & Stoler, D. L. (2003) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.129.1.96 · Cited by 54
Pályi, I., Péter, I., Daubner, D., Vincze, B., & Lõrincz, I. (1993) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02899271 · Cited by 34
[Characterization of a human cell line from an anaplastic carcinoma of the thyroid gland].
Gioanni, J., Zanghellini, E., Mazeau, C., Zhang, D., Courdi, A., Farges, M., Lambert, J. C., Duplay, H., & Schneider, M. (1991) · PubMed · Cited by 32
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
Self-citation
Metadata
- Authors
- Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., Santoro, M., Fagin, J. A., & Nikiforov, Y. E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-11-01
- Volume
- 88
- Issue
- 11
- Pages
- 5399-5404
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2104875539
- Cited by
- 1,042
- References
- 26
- FWCI
- 32.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.